All sources
Every source cited anywhere on this site, grouped by type. Each link was opened or checked against its registry or database on 15 November 2026. Company press releases are labeled "company-reported". Numbers in square brackets such as [doc ref 17] point to the reference list in the source document this site was built from.
Guidelines and regulators
- guideline KDIGO: KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis [doc ref 1]. Cited on: /, /anca-vasculitis-family/, /care-team/, /family/, /family/how-friends-can-help/, /family/what-to-tell-friends/
- guideline commentary KDOQI / KDIGO: KDOQI commentary on the KDIGO 2024 ANCA vasculitis guideline [doc ref 47]. Cited on: /faq/, /mpa/dialysis/, /mpa/kidney-flare/dialysis-during-a-flare/
- guideline Annals of the Rheumatic Diseases (2024): EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update [doc ref 40]. Cited on: /mpa/diagnosis/
- guideline Rheumatology (2025): 2025 British Society for Rheumatology recommendations for ANCA-associated vasculitis [doc ref 40]. Cited on: /anca-vasculitis-family/, /faq/, /first-30-days/, /mpa/diagnosis/, /mpa/diagnosis/first-appointment/, /mpa/diagnosis/tests/
- guideline KDIGO: KDIGO 2024 Clinical Practice Guideline for chronic kidney disease [doc ref 48]. Cited on: /faq/, /mpa/ckd/, /mpa/ckd/treatment-choices/, /mpa/dialysis/, /mpa/lifelong/
- guideline VA/DoD: Clinical practice guideline for chronic kidney disease, provider summary (2025) [doc ref 10]. Cited on: /mpa/ckd/, /mpa/lifelong/, /mpa/other-organs/damage-and-side-effects/
- guideline American College of Rheumatology: ACR guideline for the management of reproductive health in rheumatic and musculoskeletal diseases [doc ref 5]. Cited on: /mpa/diagnosis/first-appointment/, /mpa/kidney-flare/treatment/
- guideline PubMed: EULAR update on use of antirheumatic drugs in reproduction, pregnancy and lactation [doc ref 6].
- guideline Society for Maternal-Fetal Medicine: SMFM Consult Series #66: pregnancy after transplant [doc ref 4]. Cited on: /faq/, /mpa/lifelong/
- guideline BMC Nephrology (2019): Clinical practice guideline on pregnancy and renal disease [doc ref 14]. Cited on: /faq/
- guidance International Pediatric Transplant Association: Management of the paediatric kidney transplant recipient, 2026 [doc ref 8]. Cited on: /mpa/transplant/, /mpa/transplant/mpa-timing-and-recurrence/
- consensus guideline Transplantation (2024): Second International Consensus Guidelines on the management of BK polyomavirus in kidney transplantation [doc ref 8]. Cited on: /mpa/transplant/mpa-timing-and-recurrence/
- consensus Transplant International (2023): Post-transplant monitoring of donor-specific antibodies: consensus report [doc ref 32]. Cited on: /mpa/transplant/mpa-timing-and-recurrence/
- professional society American Society of Transplant Surgeons: Position statement on donor-derived cell-free DNA [doc ref 9]. Cited on: /mpa/transplant/mpa-timing-and-recurrence/
- government CMS: Medicare Part B immunosuppressive drug benefit [doc ref 13]. Cited on: /mpa/transplant/mpa-timing-and-recurrence/, /support/
- government policy HRSA / OPTN: OPTN policies [doc ref 50]. Cited on: /faq/, /mpa/transplant/
- regulator U.S. FDA: Drug Safety Communication: serious liver injury in patients taking Tavneos (avacopan) [doc ref 18]. Cited on: /research/, /research/avacopan/
- regulator U.S. FDA: CDER proposes to withdraw approval of TAVNEOS [doc ref 18]. Cited on: /research/, /research/avacopan/
- regulator European Medicines Agency: Tavneos: Article 20 referral (CHMP opinion and European Commission final decision) [doc ref 20]. Cited on: /research/, /research/avacopan/
- drug label U.S. FDA: CellCept (mycophenolate mofetil) prescribing information [doc ref 6].
- drug label DailyMed (NLM): Rituxan (rituximab) U.S. prescribing information [doc ref 37]. Cited on: /family/, /mpa/kidney-flare/treatment/
Government and patient education
- government NIDDK (NIH): Glomerular diseases.
- government NIDDK (NIH): Chronic kidney disease tests and diagnosis. Cited on: /glossary/, /mpa/diagnosis/tests/
- government NIDDK (NIH): Kidney failure: treatment comparison chart [doc ref 45]. Cited on: /care-team/, /faq/, /glossary/, /mpa/ckd/, /mpa/ckd/treatment-choices/, /mpa/dialysis/
- government NIDDK (NIH): Hemodialysis. Cited on: /mpa/ckd/treatment-choices/, /mpa/dialysis/, /mpa/kidney-flare/dialysis-during-a-flare/
- government NIDDK (NIH): Peritoneal dialysis [doc ref 46]. Cited on: /mpa/ckd/treatment-choices/, /mpa/dialysis/, /mpa/dialysis/access-warning-signs/, /urgent-symptoms/
- government NIDDK (NIH): Conservative management of kidney failure [doc ref 48]. Cited on: /mpa/ckd/treatment-choices/
- government NIDDK (NIH): Kidney transplant [doc ref 49]. Cited on: /family/hospital-stay/, /faq/, /mpa/ckd/, /mpa/ckd/treatment-choices/, /mpa/lifelong/, /mpa/transplant/
- patient organization Vasculitis Foundation: Microscopic polyangiitis (MPA) [doc ref 7]. Cited on: /, /anca-vasculitis-family/, /egpa/, /family/what-to-tell-friends/, /glossary/, /gpa/
- patient organization American Kidney Fund: ANCA vasculitis.
- rare disease database Orphanet: Microscopic polyangiitis [doc ref 34]. Cited on: /, /what-is-mpa/
- patient organization National Kidney Foundation: Hemodialysis access [doc ref 46]. Cited on: /mpa/dialysis/, /mpa/dialysis/access-warning-signs/, /urgent-symptoms/
- patient organization National Kidney Foundation: How to find a transplant center [doc ref 49]. Cited on: /support/
- patient organization American Kidney Fund: Guide to kidney transplant (2026) [doc ref 50]. Cited on: /mpa/transplant/
- professional society American Society of Transplantation: Pediatric transition portal: managing my health [doc ref 2]. Cited on: /family/hospital-stay/, /mpa/lifelong/, /mpa/transplant/, /tools/hospital-checklist/
- professional society American Society of Transplantation: Pediatric transition portal: managing my health care needs [doc ref 11]. Cited on: /family/, /mpa/lifelong/, /mpa/transplant/mpa-timing-and-recurrence/
- government Medicare.gov: End-stage renal disease (ESRD) coverage. Cited on: /support/
- government ClinicalTrials.gov: Learn about clinical studies. Cited on: /research/, /research/how-to-read-a-study/
- government NIH: NIH Clinical Research Trials and You: the basics. Cited on: /research/how-to-read-a-study/
Pivotal trials and cohort studies
- randomized trial New England Journal of Medicine (2020): PEXIVAS: plasma exchange and glucocorticoids in severe ANCA-associated vasculitis [doc ref 17]. Cited on: /mpa/kidney-flare/steroids/, /mpa/kidney-flare/treatment/
- randomized trial Annals of the Rheumatic Diseases (2023): RITAZAREM: rituximab versus azathioprine for maintenance in relapsing AAV [doc ref 39]. Cited on: /mpa/kidney-flare/treatment/
- randomized trial Arthritis & Rheumatology (2019): BREVAS: belimumab and azathioprine for maintenance of remission in AAV [doc ref 42]. Cited on: /mpa/kidney-flare/treatment/, /research/
- review Frontiers in Pharmacology (2024): Biological agents in the treatment of ANCA-associated vasculitis (review of pivotal trials) [doc ref 38]. Cited on: /mpa/kidney-flare/treatment/
- peer-reviewed Kidney International Reports (2025): Outcomes after kidney transplantation in ANCA-associated renal vasculitis (French multicenter study) [doc ref 3]. Cited on: /faq/, /mpa/transplant/mpa-timing-and-recurrence/
- peer-reviewed Clinical Journal of the American Society of Nephrology (2026): Kidney transplantation in childhood-onset ANCA-associated vasculitis: long-term outcomes [doc ref 31]. Cited on: /faq/, /mpa/transplant/mpa-timing-and-recurrence/
- peer-reviewed Arthritis & Rheumatology (2025): Renal disease in pediatric-onset ANCA-associated vasculitis: course, outcomes and predictors [doc ref 35]. Cited on: /mpa/kidney-flare/
- peer-reviewed Arthritis Care & Research (2025): Rituximab versus cyclophosphamide induction in childhood-onset AAV (ARChiVe) [doc ref 36].
- peer-reviewed Journal of Nephrology (2025): Pregnancy after kidney transplantation: registry data from three continents [doc ref 15]. Cited on: /faq/
- peer-reviewed Clinical Transplantation (2026): Common gynecologic issues in patients post-kidney transplantation [doc ref 12]. Cited on: /mpa/transplant/mpa-timing-and-recurrence/
- review Pathologica (2024): Pulmonary pathology in vasculitis [doc ref 51]. Cited on: /mpa/diagnosis/, /mpa/diagnosis/biopsy-and-other-tests/, /mpa/lifelong/relapse-signs/, /mpa/other-organs/
- peer-reviewed EBioMedicine (2026): Exploration of the genetic architecture of ANCA-associated vasculitis [doc ref 33]. Cited on: /faq/, /what-is-mpa/
- systematic review International Journal of Nephrology (2025): Biomarkers detecting the activity of AAV: systematic review [doc ref 44].
- peer-reviewed Frontiers in Immunology (2026): Proteome profiling identifies circulating biomarkers for disease activity in AAV [doc ref 44].
- randomized trial American Journal of Transplantation (2025): Induction of immune tolerance in living related HLA-matched kidney transplantation: phase 3 randomized trial [doc ref 27]. Cited on: /research/
- peer-reviewed Lancet Regional Health – Europe (2026): Felzartamab in antibody-mediated kidney transplant rejection: phase 2 extension [doc ref 26]. Cited on: /research/
- journal notice PubMed record of NEJM notice (29 Jun 2026): Retraction: Jayne DRW et al. Avacopan for the treatment of ANCA-associated vasculitis (ADVOCATE) [doc ref 19]. Cited on: /research/, /research/avacopan/, /research/how-to-read-a-study/
Latest research (checked 15 Nov 2026)
- patient organization Vasculitis Foundation: TAVNEOS (avacopan) update for the vasculitis community. Cited on: /research/avacopan/
- company-reported Amgen: TAVNEOS update (company statement and FAQ). Cited on: /research/avacopan/
- company-reported Amgen via SEC EDGAR: Amgen third-quarter 2026 earnings release (filed 3 Nov 2026) [doc ref 21]. Cited on: /research/avacopan/
- trial registry ClinicalTrials.gov: NCT07388277: CC-97540 (CD19 CAR T) in ANCA-associated vasculitis [doc ref 22]. Cited on: /faq/, /research/
- case report Kidney International Reports (2025): Point-of-care anti-CD19 CAR T-cell therapy induces renal remission in refractory MPO-ANCA vasculitis (letter, one patient) [doc ref 22]. Cited on: /research/
- case report Rheumatology (2026): Anti-CD19 CAR T-cell therapy in ANCA-associated vasculitis (one patient with relapsing GPA). Cited on: /research/
- conference abstract International Journal of Rheumatic Diseases (2026, congress abstract): Tandem CD19-BCMA CAR-T therapy in refractory ANCA-associated vasculitis. Cited on: /research/
- review Best Practice & Research Clinical Rheumatology (2026): CAR-T cell therapy for ANCA-associated vasculitis: rationale, current evidence, and future directions. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT07746180: obinutuzumab beta with low-dose glucocorticoid in new-onset ANCA glomerulonephritis [doc ref 24]. Cited on: /research/
- trial protocol BMJ Open (2024): ObiVas protocol: obinutuzumab versus rituximab in ANCA-associated vasculitis [doc ref 23]. Cited on: /research/
- company-reported Genentech (press release, 19 Oct 2025): FDA approves Gazyva for lupus nephritis. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT06388941: iptacopan in active ANCA-associated vasculitis. Cited on: /research/
- conference abstract ASN Kidney Week 2026: Abstract SA-OR077: iptacopan in active AAV, interim renal-focused results (24 Oct 2026). Cited on: /research/
- company-reported InflaRx (press release, Nov 2021): Phase II IXCHANGE study of vilobelimab in AAV. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT07168161: BDB-001 phase III trial in ANCA-associated vasculitis. Cited on: /research/
- company-reported InflaRx (press release, Nov 2026): InflaRx highlights izicopan development path in ANCA-associated vasculitis. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT07904806: VIS954 in ANCA-associated vasculitis [doc ref 41]. Cited on: /research/
- trial registry EU Clinical Trials Information System: PREP-ANCA (2025-522049-23-00): surveillance vs pre-emptive rituximab when ANCA reappears [doc ref 41]. Cited on: /mpa/lifelong/relapse-signs/, /research/
- trial summary NHS Health Research Authority: COMBIVAS research summary [doc ref 42]. Cited on: /research/
- peer-reviewed Nature Communications (2024): Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis. Cited on: /research/, /research/ai/
- trial registry ClinicalTrials.gov: NCT06685757: felzartamab in antibody-mediated kidney transplant rejection (TRANSCEND) [doc ref 25]. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT07444489: felzartamab long-term extension (TRANSCEND/TRANSPIRE LTE) [doc ref 43]. Cited on: /research/
- company-reported Hansa Biopharma (press release, 18 Feb 2026): BLA for imlifidase accepted by the FDA. Cited on: /research/
- company-reported Hansa Biopharma (press release, 4 Mar 2026): PDUFA action date for imlifidase BLA set for December 19, 2026. Cited on: /research/
- company-reported Eledon via SEC EDGAR: Eledon third-quarter 2026 results (Exhibit 99.1). Cited on: /research/
- trial registry ClinicalTrials.gov: NCT07835581: tegoprubart vs tacrolimus in kidney transplantation (LEGACY). Cited on: /research/
- peer-reviewed Kidney International Reports (2025): Explainability of a deep learning-based classification model for ANCA-associated glomerulonephritis. Cited on: /research/ai/
- conference abstract Laboratory Investigation (2026, abstract): Pathomics pipeline for medical kidney biopsy with KidneyVision. Cited on: /research/ai/
- peer-reviewed Annals of the Rheumatic Diseases (2026): Estimating 2-year risk of first relapse in AAV: risk-prediction model from PEXIVAS participants. Cited on: /research/ai/
- peer-reviewed Clinical and Experimental Rheumatology (2026): Patient-reported outcomes in a clinical risk score to improve relapse prediction in AAV. Cited on: /research/ai/
- peer-reviewed Kidney360 (2024): ANCA Kidney Risk Score performance in a German cohort. Cited on: /mpa/diagnosis/biopsy-and-other-tests/, /research/ai/
- peer-reviewed Frontiers in Digital Health (2026): Radiomics-based prediction of renal prognosis in AAV. Cited on: /research/ai/
- peer-reviewed Nature Communications (2024): Matching patients to clinical trials with large language models (TrialGPT). Cited on: /research/ai/
- government NIH (news release): NIH-developed AI algorithm matches potential volunteers to clinical trials. Cited on: /research/ai/
- peer-reviewed Annals of the Rheumatic Diseases (2023): New risk loci shared across systemic vasculitides point to potential drug-repurposing targets. Cited on: /research/ai/
Support, research networks and practical help
- patient organization Vasculitis Foundation: Find support. Cited on: /family/, /first-30-days/, /support/
- patient organization Vasculitis Foundation: Navigating Your Vasculitis Journey course. Cited on: /first-30-days/, /support/
- patient organization Vasculitis Foundation: Find a doctor [doc ref 30]. Cited on: /mpa/diagnosis/first-appointment/, /support/
- patient organization National Kidney Foundation: NKF PEERs peer mentoring. Cited on: /first-30-days/, /support/
- patient organization National Kidney Foundation: NKF Cares help line. Cited on: /support/
- government SRTR (HRSA): Find a transplant center. Cited on: /support/
- patient organization NORD: Patient assistance programs. Cited on: /family/, /support/
- patient organization American Kidney Fund: Safety net grants. Cited on: /family/, /support/
- research network Vasculitis Foundation: Vasculitis Patient-Powered Research Network (VPPRN). Cited on: /research/, /support/
- research network Vasculitis Clinical Research Consortium: VCRC team [doc ref 30]. Cited on: /research/
- research network European Vasculitis Society: EUVAS. Cited on: /research/
- trial registry ClinicalTrials.gov: NCT02593565: Vasculitis Pregnancy Registry [doc ref 30]. Cited on: /support/
- registry Transplant Pregnancy Registry International: Transplant Pregnancy Registry International [doc ref 16]. Cited on: /support/
- database NLM: PubMed.
- trial registry ClinicalTrials.gov: Search: microscopic polyangiitis. Cited on: /research/
- trial registry EU CTIS: Search for clinical trials. Cited on: /research/
- crisis line 988 Suicide & Crisis Lifeline: 988 Lifeline. Cited on: /family/, /first-30-days/, /mpa/kidney-flare/steroids/, /urgent-symptoms/
- government ADA.gov (U.S. DOJ): Introduction to the Americans with Disabilities Act. Cited on: /family/, /support/
- government U.S. Department of Labor: Family and Medical Leave Act. Cited on: /family/, /support/
- government U.S. Department of Education: Section 504. Cited on: /support/
- caregiver organization Family Caregiver Alliance: Family Caregiver Alliance. Cited on: /family/, /support/
Changelog
- 15 November 2026: first edition published; all sources checked; avacopan regulatory status checked against FDA, EMA, Amgen and Vasculitis Foundation pages.